dr. antonarakis on galeterone for prostate cancer
Published 8 years ago • 316 plays • Length 1:24Download video MP4
Download video MP3
Similar videos
-
1:05
dr. antonarakis on pd-1/pd-l1 monotherapy in prostate cancer
-
1:22
dr. antonarakis on implications of an mmr deficiency in prostate cancer
-
1:04
dr. emmanuel s. antonarakis on the future of the ar-v7 biomarker in prostate cancer
-
1:20
dr. antonarakis on ar-v7 and resistance to enzalutamide and abiraterone in prostate cancer
-
1:41
dr. antonarakis on ar-v7 and resistance to ar-targeting agents in mcrpc
-
1:42
dr. emmanuel antonarakis on sequencing adt and sipuleucel-t
-
4:27
dr. emmanuel antonarakis on the unique attributes of the taxynergy study
-
1:32
dr. antonarakis discusses ar-v7 and response to taxanes in men with mcrpc
-
3:21
dr. antonarakis on sequencing adt and sipuleucel-t in biochemically recurrent prostate cancer
-
3:11
prostate cancer: advice for oncologists on ar-v7 testing
-
3:21
predicting pd-1 checkpoint inhibitor sensitivity in prostate cancer: potential molecular biomarkers
-
3:36
john’s hopkins ar-v7 test in prostate
-
5:52
recent ar-v7 data in prostate cancer
-
1:12
antonarakis: ar-v7, taxane response in mcrpc
-
9:23
hormone-sensitive metastatic prostate cancer
-
8:15
radiopharmaceuticals in prostate cancer
-
1:07
dr. penson on treatment selection in metastatic hormone-sensitive prostate cancer
-
1:18
dr. einstein on immune therapy in prostate cancer
-
3:18
keynote-199: an update on pembrolizumab for mcrpc